BridgeMD
New treatment option for Ischemic Stroke
Official title CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke - HIBISCUS-STROKE II
ClinicalTrials.gov ID: NCT05263804
What this study is testing
- What it's testing
- Ischemic stroke is the first cause of acquired disability of the adult, the second cause of dementia and the third cause of death in the industrialized countries, what constitutes à major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an ischemic mechanism (85% of the cases) or hemorrhagic mechanism (15%).
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Ischemic Stroke confirmed by MRI
- Proximal arterial occlusion (M1 and/or M2)
- Eligible for thrombolysis and/or thrombectomy
- Informed consent signed by the patient or the next of kin
You likely can't join if
- Patients for whom it is known at the inclusion that follow-up at 3 months will not be possible at Pierre Wertheimer Hospital (Lyon, France)
- Patient with progressive or uncontrolled cancer.
- Deprivation of civil rights
- Pregnant woman or woman of childbearing age without proof of the absence of a current pregnancy
- For patients participating in the optional fecal library: factors leading to a potential change in microbiota (antibiotic therapy within 3 months...
- Contraindication to MRI with gadolinium injection
See the full eligibility criteria
- Age ≥ 18 years
- Ischemic Stroke confirmed by MRI
- Proximal arterial occlusion (M1 and/or M2)
- Eligible for thrombolysis and/or thrombectomy
- Informed consent signed by the patient or the next of kin
- Patient with a social security number Ancillary Study
- Eligible for the Hibiscus stroke II cohort
- Ancillary study informed consent signed by the patient or the next of kin
- Patients for whom it is known at the inclusion that follow-up at 3 months will not be possible at Pierre Wertheimer Hospital (Lyon, France)
- Patient with progressive or uncontrolled cancer.
- Deprivation of civil rights
- Pregnant woman or woman of childbearing age without proof of the absence of a current pregnancy
- For patients participating in the optional fecal library: factors leading to a potential change in microbiota (antibiotic therapy within 3 months, probiotic or rebiotic use within 3 months, ileo or gastrostomy...
- Contraindication to MRI with gadolinium injection
- Contraindication to cardiac MRI (including inability to perform cardiac MRI)
- Patients with a glomerular filtration rate \<30ml/min
- History of coronary artery disease
The study team makes the final eligibility decision.
Where it's taking place
- Bron, France
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bron, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.